Enterotoxigenic Escherichia Coli (ETEC) strains are the commonest bacteria causing diarrhea in children in developing countries and travelers to these areas. Colonization factors (CFs) and enterotoxins are the main virulence determinants in ETEC pathogenesis. Heterogeneity of CFs is commonly considered the bottleneck to developing an effective vaccine. It is believed that broad spectrum protection against ETEC would be achieved by induced anti-CF and anti-enterotoxin immunity simultaneously. Here, a fusion antigen strategy was used to construct a quadrivalent recombinant protein called 3CL and composed of CfaB, a structural subunit of CFA/I, and CS6 structural subunits, LTB and STa toxoid of ETEC. Its anti-CF and antitoxin immunogenicity was then assessed. To achieve high-level expression, the 3CL gene was synthesized using E. coli codon bias. Female BALB/C mice were immunized with purified recombinant 3CL. Immunized mice developed antibodies that were capable of detecting each recombinant subunit in addition to native CS6 protein and also protected the mice against ETEC challenge. Moreover, sera from immunized mice also neutralized STa toxin in a suckling mouse assay. These results indicate that 3CL can induce anti-CF and neutralizing antitoxin antibodies along with introducing CFA/I as a platform for epitope insertion.
Enterotoxigenic ETEC, the commonest cause of noninflammatory diarrhea in developing countries, is responsible for approximately 20% of all diarrheal episodes in children in these areas (1) . It is also known as one of the main cause of diarrhea in travelers to high risk areas and is accordingly known as travelers' diarrhea (2) . Enterotoxins and CFs are major virulence factors in ETEC infections (3) . ETEC uses colonization factors to attach to the epithelial surface of the small intestine, a vital early step in diarrhea pathogenesis, and then produces enterotoxins that act on the epithelial cells.
Enterotoxins including LT and STa, disrupt intestinal fluid homeostasis and cause hyper-secretion of fluid and electrolytes through activation of adenyl cyclase by LT or guanylate cyclase by STa in intestinal epithelial cells (3) .
No effective vaccine is currently available for protecting humans and animals against ETEC infections (4) . The heterogeneity of ETEC colonization factors and potent toxicity of enterotoxins are the critical obstacles to developing effective vaccines against ETEC (5, 6) . Given that more than 25 different and immunologically heterogeneous CFs have been characterized among ETEC strains (5) , vaccines that target only one of these CFs can provide protection only against ETEC that expresses the same or homologous CFs.
The enterotoxicity potential of LT and STa decreases their opportunity to be considered as antigens for developing safe vaccines. Moreover, STa, a 19-aminoacid peptide, is a small and poorly immunogenic molecule and thus unsuitable for use as a vaccine target (6, 7) . In the case of LT, several detoxified derivatives have been introduced and used as vaccine candidates (8) (9) (10) . LTB, which has high antigenicity and adjuvanticity potentials, has been used not only in ETEC vaccines, but also in formulating other vaccines (11, 12) . Moreover, because over two-thirds of human ETEC strains are STa þ (13) and STa and LT have no epitopes in common, and because anti-LT immunity does not confer any cross-protection against STa toxin, STa antigens must be considered when attempting to design broadly effective vaccines against ETEC diarrhea (14, 15) . By removal or reducing of STa toxicity and increasing its immunogenicity, this small molecule could be used as a safe component in multimeric vaccines. (15) . Many studies have performed genetic fusion or chemical conjugation of STa peptides to an immunogenic carrier protein such as OmpC (16) or LT derivatives (10, 14, 17) to produce vaccines for inducing anti-STa immunity and demonstrated that the resultant fusion molecules are safe and can stimulate neutralizing antibodies against both STa and the carrier molecules. In this regard, several studies have also applied the CFs structural subunits as carrier molecules to develop anti-CF and anti-STa immunity (18, 19) . In fact, anti-toxin and anti-adhesin immunity can be simultaneously stimulated by adhesin-toxoid chimeric antigens (10, 14) . Recently, we designed a chimeric construct containing CfaB (CFA/I major subunit of ETEC fimbriae), CssA and CssB proteins (structural subunits of CS6) and the antigenic subunit of LT toxin, LTB, as a candidate vaccine against ETEC, designated as 3CL (20) . In this construct, STa toxoid molecule is exposed as an epitope in the CfaB structure. Zhang et al. have reported this epitope as "a shorter peptide of porcine STa toxoid STa13"; its toxicity is reduced and its anti-STa immunogenicity increased when it is fused to a LT toxoid protein. In this STa derivative, alanine is substituted for the 13th amino acid, glutamine (19) .
The bioinformatics features of this adhesin-toxoid chimeric antigen have been reported, as have the results of assessing its expression, purification and characterization by using immunoblot methods (20) . In a subsequent step, in the current study the purified fusion protein was used to immunize mice to examine its antitoxoid and anti-CFs antigenicity and ability to produce neutralizing antibodies. To evaluate the protection potential of induced immunity, the immunized mice were challenged with a LT, STa, CFA/I-producing ETEC strain. 
MATERIAL AND METHODS

Design and construction of chimeric 3CL
CfaB, CFA/I major subunit, CssA/B, CS6 subunits and LTB were selected for designing a chimeric construct. STa toxoid peptide (CCELCCNPQCTGCY) was inserted as a foreign epitope into the CfaB sequence. Bioinformatics analyses were used to select the best position for insertion of the STa toxoid and the best order of subunits in the fusion protein, as reported previously (20) . Three and four repeats of EAAAK were used as linkers to generate a multivalent chimeric protein. The concluding chimeric gene (GeneBank accession number: JX481981.1) was then synthesized and cloned into pET28a.
Molecular cloning, expression, purification and characterization of 3CL chimeric protein
Recombinant pET28þ3cl vector sub-cloned into E. coli BL21 (DE3) and recombinant 3CL protein was expressed by isopropyl b-D-1-thiogalactopyranoside induction. The fusion protein was purified by His-tagged sites at amino and carboxyl terminal sites and characterized by commercial anti-LTB mAb and anti-CfaB, anti-CssA and anti-CssB sera, which were produced in our laboratory by immunizing mice with each of the recombinant proteins. Western blot analysis was also used to characterize the chimeric protein, as described previously (20) . In this analysis native CS6 antiserum was used as the primary antibody. Moreover, the antichimeric protein serum was used as the primary antibody for detecting each of the subunit proteins and also for purifying native CS6 protein by western blotting.
Immunization of mice with purified fusion protein and antibody titration
Female BALB/C mice (6-8 weeks old) (Pasteur Institute of Iran) were used as the animal model. The animals were immunized s.c. with 10 mg purified protein in an equal volume of Freund's complete adjuvant (Sigma-Aldrich, St Louis, MO, USA). Two extra doses using Freund's incomplete adjuvant were injected at biweekly intervals as booster doses. Seven days before challenge, the animals were injected with 5 mg protein i.p. as an additional booster dose (fourth dose in total). For a control group, mice were injected with PBS instead of chimeric protein.
Blood and fecal samples were collected before each injection and the samples stored at À70°C until use. ELISA was used to titrate anti-3CL antibodies in serum samples, as described previously (21) . 3CL protein (5 mg) was coated as antigen in the wells of ELISA plates (Nunc, Roskilde, Denmark), immunized mice sera were used as primary antibodies (diluted 1:200 in PBST) and HRPconjugated goat anti-mouse IgG and HRP-conjugated goat anti-mouse IgA were used as secondary antibodies (diluted 1:40,000 and 1:10,000, respectively, in PBST). The OD was measured at 492 nm on a microplate reader (Bio-Rad, Hercules, CA, USA).
To titrate anti-3CL secretory IgA antibody, fecal samples were collected daily from each mouse and frozen at À70°C until use. For ELISA, 1 g of the collected fecal samples was mixed thoroughly with 500 mL of PBS and centrifuged (10 min, 6000 rpm, 4°C). The supernatants were serially diluted in PBST and added to the ELISA plates, which were then incubated for 1 hr at 37°C. The plates were washed three times in PBST and HRP goat anti-mouse IgA antibodies (1:10,000 in PBST) (Sigma-Aldrich) and added to the ELISA plates, which were then incubated for 30 min at 37°C and washed three times in PBST. Citrate buffer (100 mL) containing 0.06% (w/v) of o-phenylenediaminedihydrochloride (Sigma-Aldrich) and 0.06% (v/v) hydrogen peroxide were added to the wells at room temperature for 15 min. The reactions were stopped with 100 mL of 2 M H 2 SO 4 and the OD 492 read.
Suckling mouse assay for STa neutralization activity of anti-3CL serum
The potential of the antibodies from immunized mice to neutralize STa toxicity was determined using an in vivo neutralization assay in a suckling mouse model (22) . Briefly, one MU of enterotoxicity of crude culture of an ETEC STa þ strain was delineated as the minimum volume needed to cause a positive response, that is, G/C (weight ratio of Gut to the remaining Carcass) ratios of >0.090. ETEC (STa þ ) strain was grown overnight in CF medium at 37°C and 180 rpm. This culture was used to inoculate 50 mL of fresh CF medium. The culture was grown for 18 hr under 200 rpm shaking at 37°C and then centrifuged at 5000 rpm for 20 min. The supernatant was used as a STa crude source for enterotoxin. Three-day-old newborn suckling mice were separated from their mothers just before the test. Crude toxin (1 MU) was pretreated with 1:0.5 and 1:1 ratios of 3CL antiserum for 1 hr at 37°C and then inoculated intragastrically into newborn mice. The inoculated mice were kept at 25°C for 3 hr and then killed with chloroform. The abdomen was opened, the small intestines removed and weighed together and the G/C ratio calculated. Ratios of less than 0.090 were considered negative whereas those over 0.090 were considered positive.
Anti-CS6 antibody titration
To evaluate the neutralizing activity of anti-3CL serum against purified CS6, 100 ng of CS6 was coated in each well of an ELISA plate. Anti-3CL serum was used as the primary antibody (diluted 1:200 in PBST) and HRP conjugated goat anti-mouse IgG as the secondary antibody (diluted 1: 40,000 in PBST).
ETEC challenge of immunized mice
The immunized mice were challenged 6 months after the first immunization. For i.p challenge, 1 Â 10 7 CFU of wild type ETEC was diluted in 100 mL of sterile PBS and injected. The challenged animals were followed for evidence of disease and death for 7 days.
Statistical analysis
The data are presented as mean AE SD. A one-way anova was used to compare the means between groups of more than two. SPSS 21.0 software was used for performing statistical analyses. Value of P < 0.05 were considered to denote statistically significant differences and P < 0.01 clearly significant differences.
RESULTS
Characterization of chimeric protein by western blot analysis
Purified 3CL chimeric protein was characterized by detection with anti-rCfaB, anti-rCssA, anti-rCssB and anti-CS6 sera and anti-LTB antibody (5). This characterization was confirmed by detection of recombinant CfaB, CssA, CssB and LTB with anti-3CL serum in western blotting (Fig. 1a,b) . Because no CS6 þ ETEC strain is available, an ELISA (data not shown) and western blotting assay was done against purified CS6 protein to evaluate the neutralization activity of anti-3CL serum (Fig. 1b) , both of which confirmed the specificity of anti-3CL serum for native purified CS6.
Antibody responses of immunized animals to chimeric protein
The immunized mice showed a significant serum IgG response to purified 3CL protein (Fig. 2a) , however, IgAs response in sera and fecal samples did not differ significantly from controls (Fig.  2b ). As Figure 2a shows, following boosting immunization, robust antibody responses were stimulated with a peak on Day 7.
Neutralization of STa enterotoxin
Because of the poor antigenicity of STa, induction of neutralizing antibodies against it is difficult. Therefore an in vivo suckling mouse model in which the antisera of immunized animals were able to neutralize STa toxin was used to determine the neutralizing capacity of antibodies induced against STa epitope of the recombinant chimeric protein. The response in the suckling mouse assay using one MU of crude culture (G/C <0.09) was found to be negative (Fig. 3) , indicates that treating 1 MU (40 mL) of crude culture with the same ratio (1:1) of sera can neutralize the toxin, which suggests that recombinant 3CL has the potential to elicit neutralizing antibodies against STa toxin.
Challenge of immunized mice with ETEC
To evaluate whether 3CL antibodies can protect immunized mice against ETEC infection, immunized and non-immunized control groups were challenged with a lethal dose (1 Â 10 5 CFU) of ETEC (CFA/I þ , LT þ , STa þ ) by i.p. injection. The animals were monitored for 7 days for evidence of disease and mortality/survival rates. There was 100% mortality in the control group by 26 hr after challenge, whereas 70% of immunized mice survived (Fig. 4) after being lethargic and having diarrhea for 3 days. These data definitely support the potential of this chimeric protein to protect immunized mice from lethal doses of ETEC.
DISCUSSION
Colonization factors, which mediate bacterial attachment to intestinal epithelial cells, and LT and STa enterotoxins, which cause fluid and electrolyte hypersecretion in the small intestine, are the two main groups of ETEC virulence factors (23) . Hence, there are two strategies for control of ETEC infections: blocking of bacterial adherence to CF receptors and eliminating enterotoxin activity in intestinal epithelial cells (14, 24) . Inactivated whole-cell vaccines composed of E. coli strains that express a CF and a toxin antigen (25) (26) (27) (28) , or subunit vaccines that use a combination of CF and toxin antigens (29, 30) or a CF-toxin fusion protein (14, 31) can induce both anti-CF and anti-toxin immunity in their hosts. In other studies, integration of native STa peptide into ClpG (the major subunit of CS31A) (18) and STa toxoid into FaeG (the major subunit of K88ac) (19) , was shown to result in development of neutralizing anti-STa, anti-ClpG and anti-FaeG antibodies in immunized animal models (18, 19) . These findings demonstrate that applying a couple of CFs along with LTB toxin with an embedded STa epitope can stimulate not only anti-adhesins and anti-LTB, but also anti-STa immunity. Here, we genetically integrated STa13 toxoid epitope into the CfaB major subunit of E. coli CFA/I fimbriae to examine a CF platform vaccine that induces both antiSTa and anti-CfaB immunity. We also fused the sequences of CssA, CssB and LTB to the carboxyl terminal of CfaB Ã STa sequence (20) . According to studies of the toxin pattern of clinically isolated ETEC, over two-thirds of human ETEC strains are STa þ (13). Therefore, a vaccine candidate containing an effective STa toxoid may provide approximately 60-70% protection coverage against ETEC infections (6) . Expressing CfaB, CS6 structural subunits, LT and STa epitope, within CfaB structure, as a fusion protein, we produced a single antigen that can induce immunity against all of these fragments. In other words, after immunization with the chimeric recombinant protein, the mice developed antibodies that could detect each subunit in the chimeric protein (Fig. 1a,b) and also neutralize the STa toxin (Fig. 3) , demonstrating the preservation of subunit proteins' conformational epitopes in the chimeric form and more importantly, displaying STa epitopes in the CfaB Ã STa structure. That elicited antibodies can detect ETEC CFs and neutralize STa toxin in vivo does not necessarily mean that they can impede toxin loading by living bacteria. Therefore, to further strengthen our findings, we performed challenge studies to evaluate the efficiency with which these induced anti-adhesins and anti-toxin immunity provide protection against ETEC infections. Because of the reported ineffectiveness of oral challenge (32, 33) , we evaluated protective antibodies against LT, STa and CFA/I producing ETEC by i.p. challenge. We found that induced anti-adhesin (anti-CfaB) and anti-toxin (both anti-LT and anti-STa) antibodies are not only neutralizing but also protective against ETEC diarrhea. The challenge route and 70% survival rate in immunized mice is comparable with the findings of Deng et al., who found that mice had a 55%survival rate after i.p challenge (32) , and of Yang et al., who evaluated the influence of challenge routes on susceptibility to ETEC infection and concluded that intranasal (high dose) and i.p routes were effective (with 50% and 80% survival, respectively), whereas oral and intranasal (low dose) routes were ineffective in immunized mice (100% survival rate) (33) . Fig. 3 . Neutralizing activity of anti-3CL serum against STa in a suckling mouse assay. Sera from mice immunized with 3CL mixed with 1 MU of culture filtrate of STa-producing ETEC (40 mL) were used to inoculate newborn mice. Neutralizing activity was assessed by determining gut/carcass (G/C) weight ratios, a G/C ratio >0.090 being considered positive for STa enterotoxicity. Culture filtrates of STa-producing ETEC (P < 0.01) and PBS (P < 0.03) were used as controls. Data depict the mean AE SD of three independent experiments at each time point. Moreover, the endurance of the induced protection of the immunized animals (Fig. 4) 6 months after the first antigen administration clearly indicates the activation and establishment of memorial B cells, which stimulate formation of immunological memory in immunized mice (34) .
According to our ELISA results (Fig. 2a,b) , secretory IgA is not definitely required for the prevention of ETEC colonization in mice. In animals immunized s.c. with chimeric 3CL, CfaB, CssA/CssB and LTB-specific IgG were elicited without any evident antigen-specific IgA. There was no bacterial colonization following challenge (Fig. 4) . The lack of 3CL-specific IgA in feces can reportedly be overcome by high CfaB, CssA/CssB and LTB-specific serum IgG or systemic priming of the immune system, resulting in a response following challenge (21) . Recent studies have found that most IgG at mucosal surfaces is derived from the serum (35, 36) . Transudation of systemic IgG antibodies appeared to be responsible for protection of immunized mice in our study.
Efficient induction of anti-STa and anti-CfaB immunity may be achieved using CfaB as a platform for STa toxoid integration in future ETEC vaccines. Comparably, Chauhan et al. reported that insertion of cholera toxin epitope into bacterial flagella induces of anti-cholera toxin antibodies (37) . Zhang and Francis also showed that integration of detoxified STa13 epitope into the FaeG major subunit of E. coli K88ac fimbriae results in induction of anti-STa immunity (19) . Likewise, in this investigation we selected a detoxified STa13 epitope to design CfaB Ã STa fusion protein. By using a suckling mouse assay, we showed that induced anti-STa immunity is capable of neutralizing native STa and inhibiting fluid accumulation in the gut of newborn mice (32) (Fig. 3) .
We were unable to evaluate the anti-CS6 potential of immunized mice sera by in vivo assays; however, detection of native purified CS6 protein (Fig. 1b) by the immunized mice sera in immunoblot analyses strengthens the probability of sera having anti-CS6 potential in challenge studies. According to ELISA results (data not shown), anti-CssA antibody concentrations were lower than anti-CssB concentrations, which is compatible with other reports of low immunogenicity of CssA compared with CssB protein (38) . Hence, we highly recommend incorporating other prevalent CF subunits rather than CssA in chimeric construct design.
We propose that E. coli strains expressing chimeric CFA/I fimbriae in which STa13 epitope is integrated into CfaB can be used in future live attenuated ETEC vaccine designs. It is possible that the expressed chimeric CFA/I fimbriae retains its receptor binding activity in host intestine. Given that CFA/I is one of the commonest CFs in infectious ETEC strains (39) , CfaB protein also can be used as a protein carrier to increase the immunogenicity of poorly immunogenic antigens. These findings suggest that residues 74-76 of CfaB are suitable candidates for insertion of such epitopes (20) . 
